Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 15/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.67 |
| ▸ | CLK1 | P49759 | 2/20 | 0.67 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.67 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.64 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767844 | 0.90 | KIT (0.80) | KITDYRK1APIK3CAMAP3K11 | |
| SCHEMBL12763302 | 0.89 | KIT (0.78) | KITDYRK1A | |
| SCHEMBL15555716 | 0.88 | KIT (0.86) | KITDYRK1APIK3CA | |
| SCHEMBL15833788 | 0.84 | DYRK1A (0.75) | DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL15821923 | 0.84 | KIT (0.64) | KITDYRK1APIK3CA | |
| SCHEMBL15833789 | 0.83 | KIT (0.84) | KITDYRK1APIK3CA | |
| SCHEMBL8941707 | 0.82 | KIT (1.00) | KITDYRK1APIK3CAMAP3K11 | |
| SCHEMBL12763532 | 0.81 | DYRK1A (0.73) | KITDYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL12762898 | 0.81 | DYRK1A (0.66) | KITDYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL3770371 | 0.81 | DYRK1A (1.00) | DYRK1ACLK1DYRK2DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447093-B2 | 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9447093-B2 | 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9447093-B2 | 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
| WO-2014096093-A1 | 3,5-DIARYLAZAINDOLES AS DYRK1A PROTEIN INHIBITORS FOR THE TREATMENT OF COGNITIVE DEFICIENCES ASSOCIATED WITH DOWN'S SYNDROME AND WITH ALZHEIMER'S DISEASE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | DYRK1A, DYRK3, DYRK2 | KIT 4658/4885DYRK1A 1/4885CLK1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.